Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naderin for Prophylaxis of Complications in Socially Significant Diseases
NCT07671508Phase 3Completed
- Sponsor
- MIPO Clinic
- Start
- May 2013
- Primary completion
- Sep 2013
01
Overview
Phase 3, open-label trial in malignant neoplasms, Tuberculosis (TB) and hepatitis C (HCV) (2 arms), sponsored by MIPO Clinic. Primary endpoints: Incidence of Infectious Complications at 6 months, Duration of Neutropenia at 6 months and 1 more. Started May 2013; status: completed.
02
Conditions
malignant neoplasmsTuberculosis (TB)hepatitis C (HCV)
Beyond the preview
Go deeper on NCT07671508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07671508.